


**DEPARTMENT OF CHEMICAL ENGINEERING
UNIVERSITY OF CAMBRIDGE**



**Intensification of Inclusion Body
Purification and Protein Refolding**

**CHEW TIN, LEE
CHURCHILL COLLEGE**

**A DISSERTATION SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY
AUGUST 2003**

Preface

This dissertation describes work carried out at the Department of Chemical Engineering of the University of Cambridge, for the degree of Doctor of Philosophy. It is my original work except where stated in the text and includes nothing that has been submitted for any degree, diploma or other qualification at any other university. This dissertation contains approximately 46800 words and 62 figures in 206 pages. Parts of this work have been presented as follows:

Refereed Journal Articles

1. Lee CT, Mackley MR, Stonestreet P, Middelberg APJ. 2001. Protein refolding in an oscillatory flow reactor. *Biotechnol Lett* 1899-1901.
2. Lee CT, Buswell AM, Middelberg APJ. 2002. The influence of mixing on lysozyme renaturation during refolding in an oscillatory-flow and stirred-tank reactor. *Chem Eng Sci* 57(10):1679-1684.
3. Lee CT, Morreale G, Middelberg APJ. 2003. Combined in-fermenter extraction and cross-flow microfiltration for improved inclusion body processing. *Biotechnol Bioeng*. Submitted.

Conference, Oral and Poster Presentations

1. Lee CT, Middelberg APJ. 2001. Protein refolding in an oscillatory-flow-mixing reactor. The proceeding of the 10th European Congress on Biotechnology. Madrid, Spain. p180.
2. Lee CT, Stonestreet P, Malcolm MR, Middelberg APJ. 2001. Protein refolding in an oscillatory-flow-mixing reactor. 4th National Meeting on Oscillatory Flow Mixing. Cambridge, UK.
3. Lee CT, Middelberg APJ. 2002. An integrated refolding and extraction system for the production of recombinant protein from inclusion bodies. The Proceedings of the ESBES-4 Symposium Life Science and Technology. Delft, The Netherlands. p28.
4. Lee CT. 2002. The Best Oral Presentation Prize: Intensification of inclusion body purification and protein refolding. The IChemE Biochemical Engineering Subject Group Postgraduate Research Event. Cambridge, UK.
5. Lee CT, Middelberg APJ. 2003. Intensification of inclusion body purification and protein refolding. 6th Interlaken Conference on Advances in Production of Biologicals: From Gene to Market. Interlaken, Switzerland. p13.



Chew Tin Lee

August 2003

Acknowledgements

I am grateful to my supervisor Dr. Anton PJ Middelberg for his guidance, encouragement and patience throughout the study. I especially acknowledge him for correcting and providing valuable input for the write-up of this thesis. I have enjoyed working with him and benefited a great deal.

I thank Professor Malcolm Mackley for providing the oscillatory flow reactor (OFR) and the valuable advice regarding OFR work. I also thank Dr. Paul Stonestreet for the OFR rig set-up and valuable advice.

I thank my colleagues from the Bioproducts and Bioprocessing Group who have supported my research work. Especially, I am obliged to Woo-Seok, Mark and Giacomo for the technical discussion and laboratory assistance. I also thank Wen Bin, Mark, Daniel Jones, Jemma and Daniel Holland for proof reading my thesis.

Financial support by the University of Technology Malaysia and Cambridge Commonwealth Trust are acknowledged.

To my family members back home, dad (Lam Lai Lee), mum (Hua Lee Gan), brother and sisters (Chew Poh, Kent, Yee Seng, Kian Foon, Wei Wei and Yu Fu), I thank them for the moral supports. Finally, but not the least, to my husband Kok Seng whose patience and love enabled me to complete this work.

Summary

There is an increasing need to translate genomic information into commercial products through protein expression and production. Formation of the protein as solid inclusion bodies in *E. coli* is advantageous as it enables good initial purification, provided that acceptable refolding yields can be achieved. However, the recovery of active recombinant protein from complex biological mixtures via the route of IB-formation involves a series of complicated recovery steps, each of which can compromise the purity and yield of the desired product. Purification of IBs using traditional methods of homogenisation and centrifugation are difficult to automate for high-throughput applications, and are costly to scale.

Process intensification by minimising the number of unit operations without a loss of product purity is desirable to improve yield and reduce production cost. Such a process should ideally be generic, scalable, easily automated to facilitate continuous processing, and should result in an improved refolding yield. Based on these criteria, an intensified unit operation termed an integrated Membrane Oscillatory Refolding (MOR) is introduced. The integrated MOR unit consists of an oscillatory flow reactor (OFR) that is integrated with a hollow ceramic membrane for cross-flow microfiltration operation. The key is the use of innovative chemical extraction technology in a non-solubilising mode for IB release, coupled with the MOR unit that acts as a novel microfiltration unit for IB purification and protein refolding. The technologies rely only on chemical reagents and on microfiltration that can be easily scaled and automated.

The objective of this study is to establish and research the *three key process steps* essential to realise the integrated MOR unit: a non-solubilising chemical extraction method; a cross-flow microfiltration for IB recovery; and protein refolding via the hollow ceramic membrane in a novel reactor. Three of these process steps, validated using granulocyte macrophage-colony stimulating factor (GM-CSF) IBs, are successfully demonstrated and ready for integration into a single unit of MOR.

Table of Contents

Preface	i
Acknowledgements	ii
Summary	iii
Table of Contents	iv
List of Figures	x
List of Tables	xvi
Nomenclature and abbreviations	xviii
CHAPTER 1 INTRODUCTION	1
1.1 Process Intensification	2
1.2 Research Objective and Scope	5
1.3 Thesis Outline	5
CHAPTER 2 INTENSIFICATION OF INCLUSION BODY PURIFICATION AND PROTEIN REFOLDING	7
2.1 Introduction	7
2.2 The Conventional Process for Inclusion Body Processing	8
2.2.1 <i>Inefficient initial IB recovery and purification</i>	11
2.3 Combined IB Chemical Extraction and Microfiltration	11
2.4 Protocol Selection for Non-solubilising Extraction Method	14
2.4.1 <i>Case studies review</i>	14
2.4.2 <i>Protocol selection</i>	15
2.4.3 <i>Cell envelope</i>	16
2.4.4 <i>Inclusion body (IB)</i>	16
2.4.5 <i>Characteristics of common chemical reagents</i>	17
2.5 IB Recovery with Cross-flow Microfiltration	19
2.5.1 <i>General review on cross-flow microfiltration</i>	19
2.5.2 <i>Key parameters for microfiltration</i>	20
2.5.3 <i>Evaluation of microfiltration efficiency</i>	22
2.5.4 <i>Microfiltration case studies review</i>	23
2.5.5 <i>Experimental design for current microfiltration tests</i>	25

2.6	Protein Refolding in a Novel Reactor	27
	2.6.1 <i>Introduction</i>	27
	2.6.2 <i>The effect of mixing on refolding</i>	28
	2.6.3 <i>Refolding reactors claimed with improved mixing characteristic</i>	30
	2.6.4 <i>OFR as a mixing reactor for protein refolding</i>	33
	2.6.5 <i>Membrane Oscillatory Reactor</i>	39
2.7	Selection of Protein Denaturation and Refolding Protocols	41
	2.7.1 <i>Review of protein denaturation</i>	41
	2.7.2 <i>Review of refolding parameters</i>	42
	2.7.3 <i>Model Protein 1: Lysozyme</i>	45
	2.7.4 <i>Model Protein 2: Granulocyte macrophage-colony stimulating factor</i>	47
2.8	Analytical Method for Detection/Quantitation of Refolded Protein	48
	2.8.1 <i>RP-HPLC as a key tool to analyse refolding species</i>	49
CHAPTER 3 NON-SOLUBILISING CHEMICAL EXTRACTION METHOD		50
	Summary	50
3.1	Introduction	51
3.2	Materials	53
3.3	Analytical Methods	53
	3.3.1 <i>Extraction efficiency using SDS-PAGE analysis</i>	53
3.4	Molecular Biology, Host Cell and Cell Suspension Preparation	54
	3.4.1 <i>Shake flask cultures</i>	54
	3.4.2 <i>Fermentations</i>	55
3.5	Methods for Chemical Extraction	56
	3.5.1 <i>Chemical extraction benchmarking using B-PER reagent</i>	56
	3.5.2 <i>Evaluation of chemical extraction methods: denaturing selective extraction</i>	56
	3.5.3 <i>Evaluation of chemical extraction methods: non-solubilising extraction</i>	57
	3.5.4 <i>Larger scale in situ chemical extraction</i>	57
3.6	Results and Discussion	59
3.7	Conclusions	67

CHAPTER 4	COMBINED CHEMICAL EXTRACTION AND CROSS-FLOW MICROFILTRATION FOR INCLUSION BODY PURIFICATION	68
	Summary	68
4.1	Introduction	69
4.2	Materials	71
4.3	Equipment and Methods for Cross-flow Microfiltration	71
	4.3.1 <i>Exekia XLAB Microfiltration Pilot Unit and membrane selection</i>	71
4.4	Analytical Methods	74
	4.4.1 <i>Total protein assay for evaluating microfiltration efficiency</i>	74
	4.4.2 <i>Agarose gel electrophoresis</i>	74
	4.4.3 <i>RP-HPLC analysis</i>	75
	4.4.4 <i>Refolding yield calculation</i>	75
4.5	Methods for Microfiltration	76
	4.5.1 <i>Methods for Benzonase treatment</i>	76
	4.5.2 <i>Microfiltration of un-treated chemical extraction broth</i>	77
	4.5.3 <i>Microfiltration of sheared chemical extraction broth</i>	77
	4.5.4 <i>Microfiltration of Benzonase-treated chemical extraction broth</i>	78
	4.5.5 <i>Clean water flux measurement and membrane regeneration</i>	78
4.6	Methods for Protein Denaturation and Refolding	79
4.7	Results and Discussion	80
	4.7.1 <i>Microfiltration tests</i>	80
	4.7.2 <i>Denaturation and refolding of GM-CSF</i>	85
4.8	Further Discussion on the Combined Extraction and Microfiltration Technology	87
4.9	Conclusions	91
CHAPTER 5	CHARACTERISATION OF OSCILLATORY FLOW REACTOR FOR PROTEIN REFOLDING AND INVESTIGATION OF MIXING EFFECT ON REFOLDING	93
	Summary	93
5.1	Introduction	94
5.2	Materials and Methods	96
	5.2.1 <i>Materials</i>	96
	5.2.2 <i>Denaturation and reduction of lysozyme</i>	96

5.2.3	<i>RP-HPLC analysis of lysozyme and refolding yield calculation</i>	96
5.2.4	<i>Activity assay</i>	96
5.2.5	<i>Fed-batch mode refolding in an OFR</i>	97
5.2.6	<i>Fed-batch refolding in a stirred-tank reactor</i>	98
5.2.7	<i>Batch scale refolding</i>	100
5.3	Results and Discussion	101
5.4	Conclusions	108
CHAPTER 6 MEMBRANE OSCILLATORY REACTOR		109
	Summary	109
6.1	Introduction	111
6.2	Materials and Experiments	112
6.2.1	<i>Materials</i>	112
6.2.2	<i>Design and basic operation of the MOR</i>	112
6.2.2.1	<i>Flow characterisation</i>	120
6.2.3	<i>Analytical method – reversed phase-HPLC</i>	121
6.2.4	<i>Clean water flux measurement and membrane regeneration</i>	123
6.2.5	<i>Characterisation of MOR as a refolding reactor with lysozyme</i>	124
6.2.5.1	<i>Denaturation and reduction of lysozyme</i>	124
6.2.5.2	<i>Lysozyme transmission test</i>	124
6.2.5.3	<i>MOR refolding of lysozyme</i>	125
6.2.5.4	<i>Refolding of lysozyme in a fed-batch stirred-tank</i>	126
6.2.6	<i>MOR refolding of GM-CSF</i>	127
6.2.6.1	<i>Preparation of GM-CSF IB</i>	127
6.2.6.2	<i>Preparation of denatured-reduced GM-CSF</i>	127
6.2.6.3	<i>Fed-batch MOR refolding of crude, and clarified denatured-reduced GM-CSF</i>	128
6.2.6.4	<i>Control experiment – batch refolding of GM-CSF</i>	128
6.2.6.5	<i>Analysis of refolded GM-CSF by RP-HPLC</i>	129
6.2.7	<i>Characterisation of MOR as an improved mixing reactor</i>	129
6.3	Results and Discussion	130
6.3.1	<i>MOR refolding of lysozyme</i>	130
6.3.1.1	<i>Transmission of denatured-reduced lysozyme</i>	130
6.3.1.2	<i>Lysozyme refolding under aggregating conditions in the MOR and FB-STR</i>	131

6.3.1.3	<i>Refolding of lysozyme under non-aggregating refolding conditions in the MOR and FB-STR</i>	134
6.3.1.4	<i>Conclusions</i>	137
6.3.2	<i>MOR and batch refolding of GM-CSF</i>	138
6.3.2.1	<i>The effect of aeration on refolding yield during sample incubation</i>	143
6.3.2.2	<i>Conclusions</i>	151
6.3.3	<i>Investigation of MOR as an improved mixing reactor</i>	151
6.4	Overall Conclusions	153
 CHAPTER 7 OVERALL DISCUSSION, FUTURE WORK AND OVERALL CONCLUSIONS		154
7.1	Overall Discussion	154
7.2	Potentials and Advantages of the MOR	155
7.2.1	<i>A fully automated MOR platform</i>	155
7.2.2	<i>A miniaturised lab-on-a-chip</i>	157
7.2.3	<i>Protection against proteolytic degradation</i>	158
7.3	Future Work	159
7.3.1	<i>Integration of all three process steps in a single MOR unit</i>	159
7.3.2	<i>Optimisation of microfiltration performance</i>	159
7.3.3	<i>Investigation of the ceramic membrane as a generic perfusion device for denatured-protein</i>	160
7.3.4	<i>Generality of the non-solubilising chemical extraction method</i>	160
7.3.5	<i>MOR as a scalable and efficient mixing reactor for refolding</i>	161
7.4	Overall Conclusions	162
 REFERENCES		165
 APPENDICES		178
Appendix 1	Plasmid Transformation	178
Appendix 2	B-PER Extraction	179
Appendix 3	Total Protein Assay	180
Appendix 4	RP-HPLC Calibration Curves for GM-CSF Analysis: For Section 4.4.3, Chapter 4	182
Appendix 5	RP-HPLC Calibration Curves for GM-CSF Analysis: For Section 6.2.3, Chapter 6	186
Appendix 6	Amino Acid Analysis for Denatured GM-CSF	190

Appendix 7	Cleaning-In-Place for the Ceramic Membrane and XLAB3 Microfiltration Unit	192
Appendix 8	Total Protein Assay for the Microfiltration Tests (Chapter 4)	194
Appendix 9	Standard Curves for Native Lysozyme	198
Appendix 10	Detail Calculation and Error Analysis for Protein Transmission in the MOR with Crude and Clarified GM-CSF as Feed	203

List of Figures

Figure 1-1	The novel Membrane Oscillatory Reactor (MOR) developed based on integration of an oscillatory flow reactor and a hollow ceramic membrane. The enlarged cross sectional view of the reactor and the efficient mixing pattern generated within the reactor are also illustrated.	3
Figure 2-1	The conventional approach for producing recombinant protein following expression as an inclusion body in <i>E. coli</i> (Optional unit operations are enclosed by dotted lines) (Datar et al., 1993).	8
Figure 2-2	Two key intensified process routes are achievable using either solubilise-then-purify method or purify-then-solubilise method.	12
Figure 2-3	(a) Normal microfiltration mode; (b) cross-flow microfiltration mode.	19
Figure 2-4	(a) A hollow ceramic membrane continuous refolding reactor developed by Katoh and Katoh (2000); (b) series of small CSTRs with side parallel feeding.	32
Figure 2-5	Typical layout of an OFR and the basic baffle design.	34
Figure 2-6	Mechanism of fluid mixing in an OFR with single-orifice baffles upon (a) upward stroke; and (b) downward stroke; (c) efficient oscillatory flow mixing pattern (Mackley, 1991).	35
Figure 2-7	Scaled-up OFR using multiple-orifice baffle (b) gave comparable mixing characteristics compared to multiple smaller OFRs bundled together (a).	36
Figure 2-8	Oxidised and reduced glutathione (GSSG/GSH) employed as a redox couple to promote thiol exchange. Protein (P) with thiol groups (-SH) reacts with GSSG to form (a) the mixed disulphide before forming (b) the protein with a native disulphide bond. Protein with a mixed disulphide (a) may also form the misfolded form of protein having a non-native disulphide bond (c).	44
Figure 3-1	SDS-PAGE analysis for the 1 st -stage soluble protein extraction based on the selective chemical extraction method developed by Falconer et al. (1999). 1, RP-HPLC purified GM-CSF control IBs provided by Novartis Pharma AG; 2, induced whole cells; 3, uninduced whole cells; 4, supernatant sample using B-PER; 5, pellet sample using B-PER; samples 6, 7 and 8 were the supernatant samples of the 1 st -stage extraction broth which contained 4, 6 and 8 M urea, respectively. Samples 6 to 8 also contained 20 mM 2-HEDS, 3 mM EDTA and 0.1 M Tris, pH 9.	60

- Figure 3-2 SDS-PAGE analysis of the 1st-stage soluble protein extraction based on the selective chemical extraction method developed by Falconer et al. (1999). 61
- Samples 1, 2 and 3 are the supernatant samples of the 1st-stage extraction broth which contained 1, 5 and 20 mM 2-HEDS; samples 4, 5 and 6 are the supernatant samples of the 1st-stage extraction broth which contained 1, 5 and 20 mM GSSG; samples 7, 8 and 9 are the supernatant samples of the 1st-stage extraction broth which contained 1, 5 and 20 mM of cystine. The extraction solution in all cases also contained 8 M urea, 3 mM EDTA, 0.1 M Tris (pH 9). M, marker.
- Figure 3-3 SDS-PAGE analysis for extraction protocols 2 and 3 (Table 3-1). 62
- M, Marker; C, whole cell extract; samples 1 and 2 are the supernatant and pellet samples from protocol 2 (2 M urea, 5 mM EDTA) following 30 min extraction; samples 3 and 4 are similar to 1 and 2, but following an extraction time of 60 min; samples 5 and 6 are the supernatant and pellet samples from protocol 3 (0.1% Triton X-100), following 30 min of extraction time; samples 7 and 8 are similar to 5 and 6, but following an extraction time of 60 min.
- Figure 3-4 A comparison of protocols 4 and 5 (Table 3-1). 63
- M, Marker; C, whole cell extract; samples 1 and 2 are the supernatant and pellet samples from protocol 4 (0.1% Triton X-100, 5 mM EDTA) following 30 min extraction; samples 3 and 4 are similar to samples 1 and 2, but following an extraction time of 60 min; samples 5 and 6 are the supernatant and pellet samples from protocol 5 (0.1% Triton X-100, 5 mM EDTA, 2 M urea) following 30 min extraction; samples 8 and 9 are similar to 5 and 6, but following an extraction time of 60 min.
- Figure 3-5 SDS-PAGE showing that the developed chemical extraction method using protocol 6 (0.05% Triton X-100, 5 mM EDTA, samples 5 and 6) gives comparable results to protocol 4 (0.1% Triton x-100, 5 mM EDTA, shown in samples 1 and 2 in Figure 3-4). Both results are also comparable to the control experiment using a commercial extraction reagent, B-PER (samples 3 and 4). 64
- 1, induced whole cells; 2, uninduced whole cells; 3, supernatant sample using B-PER; 4, pellet sample using B-PER; 5, supernatant sample of the developed chemical extraction; 6, pellet sample of the developed chemical extraction; M, marker

Figure 3-6	<p>SDS-PAGE of the pellet (P) and supernatant (S) samples following larger scale chemical extraction using protocol 6 (0.05% Triton X-100, 5 mM EDTA) performed in 4 L of fermentation broth. The extraction result is comparable to results for smaller scale extraction performed in a 10 mL shake flask as shown in Figure 3-5 (sample 5 for supernatant and sample 6 for pellet).</p> <p>M, marker; C, whole cell extract; P, pellet sample of extract; S, supernatant sample of extract. Samples P and S are the duplicate loadings of the same sample.</p>	65
Figure 3-7	<p>TEM images of (a) <i>E. coli</i> un-induced whole cells, (b) induced whole cells with intracellular GM-CSF IBs, and (c) chemical extract with GM-CSF IBs completely released from the cell envelopes.</p>	66
Figure 4-1	<p>Schematic diagram of a commercial cross-flow microfiltration unit, Pilot Unit X-LAB 3.</p>	72
Figure 4-2	<p>Microfiltration Pilot Unit X-LAB 3.</p>	73
Figure 4-3	<p>SDS-PAGE showing that a higher protein transmission was achieved using the 0.2 μm membrane (sample 3) compared to the 0.1 μm membrane (sample 2). Sample 1 is the cell extract or original feed for the microfiltration tests.</p>	74
Figure 4-4	<p>Flux versus time for cross-flow microfiltration runs using two-fold diluted extract (closed circles), two-fold diluted extract sheared with a hand-mixer device (open circles) and two-fold diluted extract treated with Benzonase (closed triangles).</p>	81
Figure 4-5	<p>Permeate flux profile for the concentration of final retentate, with Benzonase-treated extract as feed.</p>	82
Figure 4-6	<p>SDS-PAGE showing that the purity of IBs obtained by diafiltration is comparable to the pellet via centrifugation.</p> <p>1, whole cell chemical extract; 2, pellet sample of the chemical extracts; 3, supernatant sample of the chemical extracts; 4, pellet sample of the 2 x concentrated final retentate after three-volumes of buffer exchange; 5, supernatant sample of the 2 x concentrated final retentate after three-volumes of buffer exchange; 6, pellet sample of the final retentate (the initial extract was diluted 1:1 with TE buffer); 7, supernatant sample of the final retentate.</p>	83
Figure 4-7	<p>SDS-PAGE showing that the permeate samples (samples 3 and 4) contained no GM-CSF protein.</p> <p>1, Pellet sample of the chemical extract; 2, supernatant sample of the chemical extract; 3, permeate sample at 9 min; 4, permeate sample (accumulated) following one-volume buffer exchange; 5 and 7, pellet samples of the 2 x concentrated retentate; 6 and 8, supernatant samples of the</p>	84

	2 x concentrated retentate.	
Figure 4-8	TEM images of (a) <i>E. coli</i> chemical extract; and (b) final diafiltration retentate following 2 x concentration based on Benzonase-treated extraction broth as feed.	85
Figure 4-9	Comparable refolding results using either GM-CSF IBs recovered via diafiltration (D1) or centrifugation (D2). N1, Refolded peak using D1; N2, refolded peak using D2.	86
Figure 4-10	A comparison of the current integrated system with the conventional approach for IB processing.	88
Figure 4-11	Agarose electrophoresis results for optimising the chemical environment for Benzonase treatment.	90
	<ol style="list-style-type: none"> 1, Original extract without Benzonase, no dilution and no MgCl₂; 2, similar to 1, but with addition of 12 mM MgCl₂; 3, similar to 1, but extract was two-fold diluted; 4, similar to 1 but with addition of 6 mM of MgCl₂ and two-fold diluted; 5, two-fold diluted extract, with 10 U mL⁻¹ of Benzonase, in the presence of 6 mM MgCl₂; 6, two-fold diluted extract, with 20 U mL⁻¹ of Benzonase, in the presence of 6 mM MgCl₂; 7, two-fold diluted extract, with 30 U mL⁻¹ of Benzonase, in the presence of 6 mM MgCl₂; 8, two-fold diluted extract, with 50 U mL⁻¹ of Benzonase, in the presence of 6 mM MgCl₂. <p>Samples 1-8 were incubated for 30 min.</p> <ol style="list-style-type: none"> 9, overnight sample of 2; 10, overnight sample of 4; 11, overnight sample of 5; 12, overnight sample of 6; 13, overnight sample of 7; 14, overnight sample of 8. <p>M, DNA Marker.</p>	
Figure 5-1	A schematic diagram of the oscillatory flow reactor (OFR).	97
Figure 5-2	Experimental setup of the oscillatory flow reactor (OFR).	
Figure 5-3	A schematic diagram of the stirred-tank reactor (STR) (Buswell, 2002).	98
Figure 5-4	Comparison of the refolding curves using 8 M urea-denatured lysozyme and 8 M GuHCl-denatured lysozyme at	99

	low mixing ($Re_o = 250$) and high mixing ($Re_o = 1580$).	
Figure 5-5	Comparison of the refolding curves in both the OFR and STR at low mixing ($Re_o = 250$ for OFR and $Re_T = 730$ for STR) and high mixing ($Re_o = 1580$ for OFR and $Re_T = 6350$ for STR) following denaturation in 8 M urea.	101
Figure 5-6	HPLC chromatograms for native lysozyme, and denatured lysozyme (D) in 4.7 M, 6 M and 8 M GuHCl, and 8 M and 10.2 M urea.	102
Figure 5-7	Comparison of the refolding curves obtained at three mixing intensities ($Re_T = 730$, $Re_T = 3270$, $Re_T = 6350$) when 8 M urea or 4.7 M GuHCl were used as the denaturant.	105
Figure 6-1	A schematic diagram of the Membrane Oscillatory Reactor (MOR).	113
Figure 6-2	Membrane Oscillatory Reactor (MOR).	114
Figure 6-3	Fitting details of the ceramic membrane. (a) and (b), cross section side views of the feed inlet; (c), top view of a sealing bolt and three hollow screws.	117
Figure 6-4	Baffle design and fitting. (a) Single-orifice baffle; (b) multiple-orifice baffle; (c) baffles fitting; (d) a cross section view of the baffles fitting.	119
Figure 6-5	Chromatograms of native, refolded and denatured-reduced GM-CSF. 1, blank; 2, native GM-CSF provided by Novartis Pharma AG; 3 and 5, refolded and denatured GM-CSF purified from current study; 4, denatured GM-CSF from Novartis Pharma AG.	122
Figure 6-6	Chromatograms of refolding samples at various time for lysozyme refolding in the MOR system.	132
Figure 6-7	Chromatograms of refolding samples at various time for lysozyme refolding in the FB-STR.	133
Figure 6-8	Refolded lysozyme samples obtained from the MOR and FB-STR tests. 1 and 2 were duplicated experiments for the MOR; 3 and 4 were the duplicated experiments for the FB-STR; a and b were the duplicated HPLC injections of a same experiment.	135
Figure 6-9	A refolding peak obtained in the MOR with the crude feed (peak 1) was characterised by RP-HPLC and appears comparable to that obtained from the batch direct-dilution refolding (peak 2).	140
Figure 6-10	A refolding peak obtained in the MOR with the clarified feed (peak 1) was characterised by RP-HPLC and appears comparable to that obtained from the batch direct-dilution refolding (peak 2).	142

Figure 6-11	Refolded peaks obtained in the MOR, either stirred (peak 3) or not stirred (peak 1) during extended sample incubation, are compared against that of a batch refolding test (peak 2). All refolding tests were conducted with a same batch of crude denatured GM-CSF.	144
Figure 6-12	Refolded peaks obtained in the MOR, either stirred (peak 3) or not stirred (peak 1) during extended sample incubation, are compared against that of a batch refolding test (peak 2). All refolding tests were conducted with a same batch of clarified denatured GM-CSF.	145
Figure 6-13	Peaks 1 to 3 are the refolded samples obtained from the fed-batch stirred-tank reactor that were not stirred for 40 to 44 h following feeding. Peaks 4 to 6 are the refolded sample obtained from the fed-batch stirred-tank reactor that were stirred for 40 to 44 h following feeding.	148
Figure 6-14	Chromatograms 1 to 4 show the refolding species produced from a 100 mL MOR refolding mixture that was incubated for up to 6 days without stirring. Chromatograms 5 and 6 show the refolding species existed in a smaller volume of MOR sample (1.4 mL) that was incubated up to 4 days without stirring.	150
Figure 7-1	A schematic diagram of an automated Membrane Oscillatory Reactor (MOR).	156
Figure A.3	Standard curve for total protein assay.	181
Figure A.4-1	A chromatogram for native GM-CSF.	182
Figure A.4-2	Standard curve for native GM-CSF.	183
Figure A.4-3	Standard curve for denatured GM-CSF.	184
Figure A.4-4	RP-HPLC chromatograms for the denatured GM-CSF.	185
Figure A.5-1	Standard curve for native GM-CSF.	186
Figure A.5-2	RP-HPLC chromatograms for native GM-CSF.	187
Figure A.5-3	Standard curve for denatured GM-CSF.	188
Figure A.5-4	RP-HPLC chromatograms for denatured GM-CSF.	189
Figure A.8-1	Comparison of the theoretical and experimental data for the soluble protein (mg) retained in the retentate stream following three-volumes buffer exchange.	196
Figure A.9-1	Standard curve I for native lysozyme.	199
Figure A.9-2	RP-HPLC chromatograms for native lysozyme.	200
Figure A.9-3	Standard curve II for native lysozyme.	201
Figure A.9-4	RP-HPLC chromatograms for native lysozyme.	202

List of Tables

Table 2-1	Comparison of refolding protocols and yields for lysozyme.	45
Table 3-1	Summary of screened extraction protocols.	57
Table 4-1	Optimal and effective operating conditions for Benzonase Nuclease.	76
Table 5-1	Batch refolding results for lysozyme denatured under different conditions (after dilution, the final refolding buffer contained 1 mg mL ⁻¹ of lysozyme, 3.75 mM GSSG, 1 mM EDTA, 50 mM Tris-HCl, and different denaturant concentrations).	106
Table 6-1	Refolding results of 1 mg mL ⁻¹ of lysozyme in the Membrane Oscillatory Reactor (MOR, fed-batch mode) under aggregating and non-aggregating refolding conditions. The corresponding control experiments carried out in a fed-batch stirred-tank reactor (FB-STR) are also summarised.	136
Table A.3	Absorbance readings for the BSA standard solutions measured at 595 nm.	181
Table A.4-1	RP-HPLC analysis of different amounts of denatured GM-CSF (measured at 214 nm).	184
Table A.5-1	RP-HPLC areas, measured at 214 nm, for different amounts of native GM-CSF.	186
Table A.5-2	Denatured peak areas, measured at 214 nm, for different amounts of denatured GM-CSF.	188
Table A.7-1	Regeneration data for membrane A (used for the microfiltration of un-treated and Benzonase-treated extract, Sections 4.5.2 and 4.5.4, Chapter 4).	193
Table A.7-2	Regeneration data for membrane B (used for the microfiltration of sheared extract, Section 4.5.3, Chapter 4).	193
Table A.8-1	Total protein assay for the microfiltration with Benzonase-treated chemical extract.	194
Table A.8-2	Theoretical and experimental data for the soluble protein retained in the retentate stream.	195
Table A.8-3	Total protein assay for the microfiltration with un-treated chemical extract.	197
Table A.8-4	Total protein assay for the microfiltration with sheared chemical extract.	197
Table A.9-1	Native lysozyme peak area versus lysozyme (µg).	198
Table A.9-2	Native lysozyme peak area versus lysozyme (µg).	201

Table A.10-1	Estimation of denatured protein concentration and mass of GM-CSF in the crude feed stream of the MOR (each denatured sample was analysed in duplicate, i and ii).	203
Table A.10-2	Estimation of denatured protein concentration and mass of GM-CSF in the crude retentate stream of the MOR (each denatured sample was analysed in duplicate, i and ii).	203
Table A.10-3	Estimation of denatured protein concentration and mass of GM-CSF in the clarified feed stream of the MOR (each denatured sample was analysed in duplicate, i and ii).	205
Table A.10-4	Estimation of denatured protein concentration and mass of GM-CSF in the clarified retentate stream of the MOR (each denatured sample was analysed in duplicate, i and ii).	205

Nomenclature and abbreviations

2-HEDS	2-hydroxyethyl disulfide
B1 to B9	First baffle to the 9 th baffle
BME	β -mercaptoethanol
CMC	Critical Micelle Concentration
CWF	Clean water flux
CSTRs	Continuous stirred-tank reactors
D or d	Diameter (m or mm)
D_e	Equivalent diameter (m)
DEAE	Diethylaminoethyl
D_m	Inner diameter of a tubular ceramic membrane (m)
DO	Dissolved oxygen
DTT	Dithiothreitol
EBA	Expanded bed adsorption
EDTA	Ethylenediaminetetraacetic acid
f	Oscillation frequency (Hz)
GM-CSF	Granulocyte macrophage-colony stimulating factor
GSH	Reduced glutathione
GSSG	Oxidised glutathione
GuHCl	Guanidine hydrochloride
HGMS	High gradient magnetic separation
HR	High resolution
h	Baffle spacing (m)
IB	Inclusion body
i. d.	Internal diameter (mm)
IGF	Insulin-like growth factor
IPTG	Isopropyl β -D-1-thiogalactopyranoside
LMH	$L m^{-2} h^{-1}$
LPS	Lipopolysaccharide
MOR	Membrane oscillatory reactor
n	Number of unit operations (Figure 2-1, Chapter 2) or number of orifices (Section 2.6.4, Chapter 2)
NaOH	Sodium hydroxide
o. d.	Outer diameter, mm

OD	Optical density
OD ₆₀₀	Optical density measured at 600 nm
OFR	Oscillatory flow reactor
P1	Pressure gauge 1 (for inlet)
P2	Pressure gauge 2 (for outlet)
PES	Polyethersulfone
PVDF	Polyvinylidene fluoride
Re	Reynolds number
Re _T	Reynolds number for stirred-tank
Re _o	Oscillatory Reynolds number
r-IL-2	Recombinant interleukin-2
r-HPI	Recombinant human proinsulin
RP-HPLC	Reversed-phase high performance liquid chromatography
SEC	Size-exclusion chromatography
-SH	Cysteine residue or thiol group
SDS	Sodium dodecyl sulfate
PAGE	Polyacrylamide gel electrophoresis
STR	Stirred-tank reactor
TB	Terrific broth
TEM	Transmission electron microscopy
TFA	Trifluoroacetic acid
%T	Transmission level for microfiltration
TMP	Transmembrane pressure (bar)
tPA	Tissue plasminogen activator
Triton X-100	t-octylphenoxypolyethoxyethanol
UV ₂₈₀	Measurement of UV absorbance at 280 nm
v	Linear velocity (m s ⁻¹)
v	Fluid kinematic viscosity (m ² s ⁻¹)
x _o	Oscillatory amplitude (centre-to-peak, m)
ω	Angular frequency (rad s ⁻¹)

CHAPTER 1

INTRODUCTION

There is an increasing need to express and purify proteins to add value to the human genome sequencing effort, and to speed up the commercialisation of new biopharmaceutical products. The bacterium *E. coli* is a widely used expression system as it offers advantages including high-level expression, known molecular biology and simple culturing procedures (Cleland, 1993). It therefore has a key role in supporting post-genomic efforts in both academic and industrial laboratories. However protein over-expressed in *E. coli* is often sequestered into biologically inactive and insoluble aggregates, known as inclusion bodies (IBs) (Marston, 1986; Mitraki et al., 1991). Despite the disadvantage of expression in an inactive form, which requires efficient *in vitro* refolding to give the bioactive product, the insoluble state facilitates primary recovery and enrichment using solid/liquid separation unit operations (e.g., centrifugation/filtration), as the target protein usually represents more than 50% of the total polypeptide content in IBs (Clark and Georgiou, 1991). Expression as an IB offers other advantages including protection against proteolytic degradation (Valax and Georgiou, 1993; Marston, 1986; Shortle and Meeker, 1989) and prevention against host cell toxicity (Clark and Georgiou, 1991).

Production of recombinant protein as an IB represents a competitive way to introduce new commercial products compared with other expression routes (e.g., soluble protein expression using mammalian cells) that are inherently more complex in terms of product expression and recovery. The 'first to market' priority means that unoptimised moderate refolding yields may be tolerated (Middelberg, 2002), although a very low refolding yield can render this expression route economically infeasible (for instance, refolding yield of < 3% reported for tissue plasminogen activator (tPA) at 2.5 mg L⁻¹) (Datar et al., 1993). Nevertheless, production via IBs becomes very competitive whenever reasonable refolding yields can be achieved. For instance, a

range of modified tPAs are now expressed as IBs in *E. coli*, e.g., Retaplastase.

Once an adequate refolding method has been established, the immediate focus becomes rapid scale-up to commercial production (Middelberg, 2002). Ideally, the process should use technology that is approximately scale-invariant, easily automated for high-throughput processing, generic for a broad range of proteins, and economical (Middelberg, 2002). However, the conventional IB processing strategy involves a series of processing steps which, for tPA, accounts for 50-70% of production cost (Datar et al., 1993). Additionally the steps may compromise product yield and thus economic feasibility (Datar, 1986). For example, a large number of downstream processing steps coupled with poor refolding yield in the tPA IB flowsheet accounted for 88% of the entire production costs (Datar et al., 1993), thereby making the IB route unfavourable.

Research is clearly needed to generate economic generic processes for protein production via the IB route. However, the generation of an optimal process is challenging as the number of alternatives and parameters that can be investigated are large (Petrides et al., 1989). A range of research strategies is available, including intensification of the downstream process to improve yield (Fish and Lilly, 1984; Koltermann et al., 1997), molecular manipulation such as fusion technology to simplify downstream processing (Steffens, 2000), use of bioprocess simulation tools to evaluate process economics based on laboratory and pilot plant data (Petrides et al., 1989), and optimisation of key unit operations (e.g., centrifugation optimisation as reported by Wong et al. (1996), and improved refolding reactor strategies as reported by Kotlarski et al. (1997)).

In this study, process intensification is employed as a key research strategy to improve current technology for IB purification and protein refolding.

1.1 Process Intensification

Process intensification by minimising the number of unit operations without a loss of product purity is desirable to improve yield and reduce production cost. Such a process should ideally be generic, scalable, easily automated to facilitate continuous processing, and should result in an improved refolding yield. Based on these criteria, a novel unit operation, termed an integrated Membrane Oscillatory Reactor (MOR) is introduced in this thesis (Figure 1-1).




Figure 1-1 The novel Membrane Oscillatory Reactor (MOR) developed based on integration of an oscillatory flow reactor and a hollow ceramic membrane. The enlarged cross sectional view of the reactor and the efficient mixing pattern generated within the reactor are also illustrated.

The MOR unit consists of an oscillatory flow reactor (OFR) that is integrated with a hollow ceramic membrane for microfiltration and perfusive refolding. For IB intensification, the key is the use of innovative chemical extraction technology in a non-solubilising mode for IB release, coupled with a MOR unit that acts as a novel

microfiltration unit, initially for IB purification and then protein refolding. The technology relies only on the use of chemical reagents and microfiltration, and can therefore be easily scaled and automated.

The concept of the MOR system is simple. Fermentation broth is first added to the holding-tank of the unit, and chemical extraction reagents are then added to disrupt the cells and release the insoluble IBs. Alternatively, chemical extraction can also be conducted in the fermenter (as described in this study), and then charged into the holding-tank for subsequent microfiltration. In both cases, soluble contaminants are then removed by operating the unit as a microfiltration unit in diafiltration mode, giving cleaned insoluble IB suspension as the retentate. The retentate is collected in the holding tank, and chemical reagents are then added to solubilise the IBs. The denatured protein from the solubilised IBs is subsequently perfused through the ceramic membrane into refolding buffer that is mixed efficiently by intense oscillation; concomitant removal of the gel-like contaminant (in the retentate), formed from residual cell debris, is achieved. By using the same membrane for microfiltration and protein perfusion, only two unit operations are required to produce substantially pure refolded protein: a fermenter and the MOR system.

The potential advantages of the MOR unit include:

- i) process intensification, as the cumbersome steps of repetitive homogenisation and centrifugation are eliminated. IB loss, due to repetitive washing steps, can be minimised;
- ii) reduced validation costs due to fewer process steps;
- iii) a potentially efficient and scalable mixing device for protein refolding;
- iv) easy scale-up, to facilitate continuous and automated operation at both laboratory and process scale, as these technologies rely only on chemical reagents and liquid-handling;
- v) minimum risk of proteolytic degradation, as the protective IB state is preserved until most of the soluble contaminants have been removed.

1.2 Research Objective and Scope

To enable the development of the integrated unit, three enabling process steps are identified and developed individually. The steps are:

- (i) an efficient non-solubilising chemical extraction method suitable for interfacing with microfiltration;
- (ii) an efficient microfiltration method to recover IBs from the chemical extract in a commercial cross-flow microfiltration unit;
- (iii) a novel refolding step in the MOR unit. Provided that the membrane used for refolding in the MOR is the same as that selected for microfiltration, process steps(ii) and (iii) can be integrated in a single MOR unit.

The key objective of this study is *to research and establish these three enabling process steps* for subsequent integration into a single MOR unit operation for IB purification and protein refolding.

An investigation into the potential of the MOR to act as an efficient dispersion device for protein refolding represents a secondary objective of the study. This is done by proving that efficient dispersion is necessary for efficient refolding, using lysozyme as a model protein in an ordinary oscillatory flow reactor (without integration of the central membrane). Experiments are conducted in parallel with control experiments using a conventional fed-batch mode stirred-tank reactor, and show that efficient dispersion is necessary. The OFR characteristic of the MOR system may thus offer significant process advantage, but this remains to be proven.

1.3 Thesis Outline

This dissertation consists of seven chapters. Chapter 2 reviews background knowledge and case studies pertinent to the development of the *three enabling process steps* for the integrated unit. The conventional process for IB recovery and protein refolding, and the corresponding key issues, are described. The review facilitates selection of experimental design for each process step while minimising the need for extensive optimisation.

Chapter 3 reports the development of a non-solubilising chemical extraction method. Extraction protocols are first screened and developed in a small-scale experiment and then validated at larger scale in a fermenter.

The successful chemical extraction method developed in Chapter 3 is coupled with a microfiltration unit for IB purification. Microfiltration protocols are developed using a commercial cross-flow microfiltration unit fitted with a hollow ceramic membrane. The microfiltration tests are reported in Chapter 4.

Prior to characterisation of the MOR unit for protein refolding in Chapter 6, Chapter 5 characterises the OFR basic reactor for protein refolding. To investigate the MOR as an improved mixing reactor in Chapter 6, the effect of mixing on refolding is also investigated in the OFR and in a stirred-tank reactor.

Chapter 6 validates the MOR as a refolding reactor using lysozyme and granulocyte macrophage-colony stimulating factor as model proteins. The potential of the MOR to constitute an improved mixing reactor for refolding is also investigated.

Chapter 7 discusses the integration of the three enabling process steps into a single MOR unit, with special focus on the *potential* of the integrated unit. Future work and overall conclusions for this study are then presented.

CHAPTER 2

INTENSIFICATION OF INCLUSION BODY PURIFICATION AND PROTEIN REFOLDING

2.1 Introduction

This chapter reviews background knowledge and case studies pertinent to the development of the *three key process steps* needed for an integrated unit: non-solubilising chemical extraction, cross-flow microfiltration, and protein refolding in a novel reactor.

The conventional process for recombinant protein production via the route of inclusion bodies (IBs) is first described. Due to the inefficiency of inclusion body (IB) recovery steps in the conventional approach, a combined chemical extraction and microfiltration method is presented to intensify the process steps. Common chemical reagents used for IB washing and cell permeabilisation (non-denaturing condition) are reviewed for their potential to constitute a disruptive but non-solubilising extraction protocol to release IBs.

Various key parameters, advantages and issues for microfiltration, and previous microfiltration studies for IB recovery, are then reviewed. The review facilitates the selection of key parameters applicable for current microfiltration operations.

Protein refolding and the key issues pertinent to this study are then reviewed. The key issue of protein aggregation during refolding and the likelihood of mixing effects on protein refolding are discussed. Several workers have proposed different reactor designs to improve mixing characteristics with the aim of increasing the refolding yield. In all cases the exact mechanism leading to mixing effects being observed are not clearly elucidated. Nevertheless, these studies confirm reactor mixing efficiency to be an important parameter requiring further research, especially upon scale-up.

A novel refolding reactor, the Membrane Oscillatory Reactor (Section 1.1, Chapter 1), potentially having effective and scalable mixing characteristics, is introduced. Background studies on protein refolding, including protein denaturation and refolding protocols and analytical methods, are reviewed to facilitate the selection of the corresponding protocols for validating the novel refolding reactor.

2.2 The Conventional Process for Inclusion Body Processing

Figure 2-1 shows the general process route to obtain active purified protein from IBs.




Figure 2-1 The conventional approach for producing recombinant protein following expression as an IB in *E. coli* (optional unit operations are enclosed by dotted lines) (Datar et al., 1993).

Figure 2-1 captures mainly the laboratory approach for IB processing, refolding and purification to produce pure bioactive protein. Several modifications are usually introduced at process scale due to economic considerations (Middelberg and O'Neill, 1998). For a given protein, variation in unit operation optimisation is likely to occur and is a function of the composition of the starting material and the characteristics of the IB (Clark and Georgiou, 1991).

Initial IB recovery

Cells containing the desired IB product are first recovered or concentrated following fermentation by means of a centrifugation or filtration step, though this step may be optional. The primary recovery of IBs employs repeated cycles of mechanical disruption, followed by repeated cycles of enzymatic and chemical treatment interspersed with centrifugal washing (Clark, 2001; Middelberg, 2002).

Cell disruption is usually repeated to micronise cell debris so that separation from the denser IBs can be facilitated using differential centrifugation (Fischer et al., 1993; Thatcher and Hitchcock, 1994; Middelberg and O'Neill, 1998). Repetitive centrifugal washing, usually with low concentrations of chaotropic reagents (e.g., 2 M urea, 1 M guanidine hydrochloride) or detergent (e.g., 0.1-5% Triton X-100) (Fischer et al., 1993), aim to remove most of the soluble contaminants (soluble cell proteins, nucleic acids, lipids and membrane vesicles) and insoluble fragments of the cell wall (e.g., peptidoglycan and associated cell-wall proteins and lipids) to provide substantially clean IB paste (Middelberg and O'Neill, 1998; Clark, 2001).

IB washing with intensive use of chemical reagents is costly both in terms of reagent and waste disposal at process-scale. Therefore, optimisation of centrifugation parameters such as feed-rate and multiple centrifuge passes without intensive use of chemical reagents will be a better strategy to improve IB purity (Wong et al., 1996). The strategy successfully improved the purity of Gly-IGF-II IBs, that were susceptible to proteolytic degradation during IB dissolution, and resulted in a net improvement in the overall protein yield following dissolution (Wong et al., 1996).

However, good fractionation of cell debris from IB sediment in the laboratory is often difficult to achieve, depending on the ease of pellet re-suspension (Middelberg, 2002). At process scale, the cumbersome and costly IB washing steps are usually simplified, resulting in reduced IB purity (Middelberg, 2002).

Dissolution and refolding

Dissolution of IBs is typically achieved using high concentrations of denaturing reagents such as urea or guanidine hydrochloride. Addition of reducing agents such as dithiothreitol or β -mercaptoethanol may be required if IB contains disulphide bonds (Rudolph and Lilie, 1996; Thatcher and Hitchcock, 1994) though reduction may not be essential for some disulphide-bonded IBs (e.g., recombinant bovine growth hormone stored in a completely reduced form (Langley et al., 1987)). The solubilised protein is then refolded to gain the native 3D structure, by lowering the denaturant concentration. Refolding can be achieved using different methods such as dilution of the protein into a large volume of refolding buffer (Rudolph, 1990; Galliher, 1991; Fischer et al, 1993) or by buffer exchange using dialysis (Kelly and Price, 1992; Fischer et al., 1993).

High-resolution purification and pre-treatment

A single step of high-resolution purification prior to refolding may be necessary to remove residual contaminants (from the denatured protein) that can induce aggregation during refolding (Maachupalli-Reddy et al., 1997). Typically this step can be achieved using high-resolution (HR) separation methods such as ion exchange, size-exclusion, metal affinity, hydrophobic or reversed-phase chromatography (Clark and Georgiou, 1991).

A pre-treatment step prior to HR purification is also generally essential to avoid excessive fouling of column resin due to the presence of residual insoluble contaminants (Clark, 1998; Middelberg and O'Neill, 1998). Separation of these impurities from the target protein dissolved in highly concentrated and viscous solution of chaotrope can be tedious (Middelberg, 2002). This can be achieved using ultracentrifugation or filtration at